Mogrify Limited (Mogrify®), a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, announced today the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round. The funding will support the advancement of Mogrify’s immuno-oncology and ophthalmology programs, as well as continued platform development and the exploration of cell reprogramming for novel therapeutic application.

Mogrify will transform the development of ex vivo cell therapy and in vivo reprogramming therapy, converting any cell type into any other.

Mogrify Completes Series A Financing Totaling $33 Million Usd

Description

Company Information